文献速递免疫规划慢病防控与筛查

实体器官移植受者伴或不伴HIV感染的SARS-CoV-2疫苗体液应答持久

Humoral SARS-CoV-2 vaccine responses are durable in solid organ transplant recipients with and without HIV.
PubMed 文献 · Vaccine · 2025-11-15

单中心前瞻性观察性队列研究纳入122例已接种两剂mRNA COVID-19疫苗并计划接种额外剂次的实体器官移植受者,其中伴HIV感染44例、不伴HIV感染78例,两组结合抗体与中和抗体滴度在基线及随访期间相当;65%受者在第三剂前已血清阳性,额外剂次和SARS-CoV-2感染使多数受者(21/27)血清转阳。

要点

  • 伴HIV(44/122,36%)与不伴HIV(78/122,64%)的实体器官移植受者结合和中和SARS-CoV-2抗体滴度在基线及随访期间相当。
  • 全部实体器官移植受者中65%在第三剂疫苗前已血清阳性;基线血清阴性27例中3例(11%)为HIV感染者。
  • 额外疫苗剂次和SARS-CoV-2感染使多数基线血清阴性者(21/27)血清转阳,仍血清阴性者(6例)均无HIV但均使用抗代谢药。

核心结论

  • 控制良好的HIV感染未显著影响实体器官移植受者的体液疫苗应答,这些发现支持伴HIV的实体器官移植受者当前的疫苗接种策略,并强调免疫抑制方案及接种时机对COVID-19疫苗诱导免疫的影响。

研究设计与样本

  • 单中心前瞻性观察性队列研究,纳入已接种两剂mRNA COVID-19疫苗并计划接种额外剂次的实体器官移植受者,伴HIV-1感染者44/122(36%),不伴HIV感染者78/122(64%)。
  • 在接种后多个时间点测量SARS-CoV-2结合抗体和中和抗体应答。

主要发现

  • 伴HIV与不伴HIV的实体器官移植受者在基线及随访期间显示相当的结合和中和SARS-CoV-2抗体滴度。
  • 全部实体器官移植受者中65%在第三剂疫苗前已血清阳性;基线血清阴性27例中3例(11%)为HIV感染者。
  • 额外疫苗剂次和SARS-CoV-2感染使多数基线血清阴性者(21/27)血清转阳;仍血清阴性者(6例)均无HIV但均使用抗代谢药。

临床怎么用

  • 作者认为这些发现支持伴HIV的实体器官移植受者当前的疫苗接种策略,并强调免疫抑制方案及接种时机对COVID-19疫苗诱导免疫的影响。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Solid organ transplant (SOT) recipients may have a suboptimal humoral immune response to the coronavirus disease 2019 (COVID-19) vaccine, prompting the need for additional doses of vaccine for immunocompromised patients. However, data on vaccine immunogenicity in SOT recipients with well controlled HIV infection remain scarce. We aimed to assess the effect of well controlled HIV infection on vaccine responses in SOT recipients, as compared to those without HIV. METHODS: We conducted a prospective observational cohort single-center study of SOT recipients with and without HIV-1 infection who had received two doses of mRNA COVID-19 vaccine and were planning to receive additional doses. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binding and neutralizing antibody responses were measured at several time points after vaccination. FINDINGS: SOT recipients with HIV (44/122, 36 %) and without HIV infection (78/122, 64 %) showed comparable binding and neutralizing SARS-CoV-2 antibody titers at baseline as well as over time. Overall, 65 % of all SOT recipients were seropositive prior to a third vaccine dose. Twenty-seven participants were seronegative at baseline; three (11 %) were participants with HIV. Additional vaccine doses and SARS-CoV-2 infections led to seroconversion in most participants (21/27). None of those who remained seronegative (N: 6) had HIV but all received antimetabolites. INTERPRETATION: Well-controlled HIV infection did not significantly affect humoral vaccine responses in SOT recipients. These findings support current vaccination strategies in SOT recipients with HIV and underscore the influence of immunosuppressive regimens as well as vaccination timing on COVID-19 vaccine-induced immunity.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Rana MM, Haydel B, Carrara G, et al. Humoral SARS-CoV-2 vaccine responses are durable in solid organ transplant recipients with and without HIV. Vaccine. 2025. PMID: 41240586. doi:10.1016/j.vaccine.2025.127969

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。